Q1 revenue growth and reiterated FY guidance support the growth narrative, but the EPS miss and continued net loss cap near-term upside. Monitor the conference call for color on tariff impact and pharma collaboration milestones. Expect range-bound trading until profitability inflection becomes visible.
Price Chart
Executive Summary
KORU Medical reported Q1 2026 revenue of $11.8M (+22% YoY), beating the implied run rate from FY guidance, but EPS of ($0.02) missed consensus ($0.01) and the company remained net loss-making. FY2026 guidance was reiterated, signaling confidence in the full-year outlook. The mixed quarter balances strong top-line growth against an EPS miss and still-negative profitability.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $11.8M, +22% YoY, above prior-year comp
- GAAP EPS ($0.02) vs consensus ($0.01), a 100% miss
- Net loss improved to ($0.8M) from ($1.2M) in Q1 2025
- Gross margin declined to 61.5% from 62.8% due to tariff and production costs
- FY2026 guidance reiterated: revenue $47.5-$50.0M, gross margin 61-63%, positive adjusted EBITDA and cash flow
- Submitted 510(k) for deferoxamine; two non-Ig collaborations advanced to Phase III
Financial Impact
Revenue grew 22% YoY to $11.8M, but EPS of ($0.02) missed consensus of ($0.01) by 100%
Risk Factors
- EPS miss could pressure the stock short-term despite revenue beat
- Gross margin declining due to tariffs and production costs may compress if raw costs rise
- Still loss-making; cash burn extends if growth slows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001161697-26-000107 |
| Document: form_8-k.htm | 0001161697-26-000107 |
| Document: 0001161697-26-000107-index-headers.html | 0001161697-26-000107 |
| Document: 0001161697-26-000107-index.html | 0001161697-26-000107 |
| Document: 0001161697-26-000107.txt | 0001161697-26-000107 |
| 8-K Data (Synthetic) | 0001161697-26-000107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 15w ago | Institutional Cluster | $4.43 $4.24 | ▼ −4.29% | ▼ −4.16% | $3.14 (−29.01%) |
Jun 30, 2026 16w ago | 8-K | $4.40 $4.59 | ▲ +4.32% | ▲ +4.06% | $3.14 (−28.52%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.18 | ▲ +0.97% | ▼ −0.63% | $3.14 (−24.03%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.06 | ▼ −1.93% | ▼ −3.78% | $3.14 (−24.03%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.18 | ▲ +0.97% | ▼ −0.63% | $3.14 (−24.03%) |
May 18, 2026 23w ago | Insider Cluster | $3.96 $4.15 | ▲ +4.80% | ▲ +2.50% | $3.14 (−20.58%) |
May 6, 2026 24w ago | 8-K | $4.44 $3.85 | ▼ −13.29% | ▼ −14.79% | $3.14 (−29.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers